Patient characteristics of the AIEOP LAM 2002/01 protocol
| Characteristic . | n . | % . |
|---|---|---|
| Number of evaluable patients | 482 | 100 |
| Gender | ||
| Male | 262 | 52 |
| Female | 220 | 48 |
| Age | ||
| <1 y | 63 | 13 |
| 1-2 y | 52 | 10 |
| 2-10 y | 181 | 38 |
| >10 y | 186 | 39 |
| WBC count (×109/L) | ||
| <10 | 171 | 35 |
| 10-99 | 236 | 49 |
| >100 | 75 | 16 |
| CNS leukemia (yes) | 40 | 8 |
| FAB subtype | ||
| M0 | 34 | 7 |
| M1 | 88 | 18 |
| M2 | 91 | 19 |
| M4 | 40 | 8 |
| M4 Eo | 43 | 9 |
| M5 | 117 | 24 |
| M6 | 5 | 1 |
| M7 | 44 | 9 |
| Unclassifiable/not known | 20 | 4 |
| Cytogenetics | ||
| Patients with available cytogenetic data | 418 | |
| Favorable cytogenetics | 99 | 24 |
| t(8;21) | 72 | 17 |
| t(16;16) | 1 | 0 |
| inv 16 | 26 | 6 |
| Translocation t(9;11) | 19 | 5 |
| Other 11q23 abnormalities | 46 | 11 |
| Complex karyotype | 27 | 6 |
| Normal | 166 | 39 |
| Other abnormalities | 61 | 15 |
| FLT3 aberrations | ||
| Patients tested for FLT3 aberrations | 384 | |
| ITD | 42 | 11 |
| Activating loop mutations (D835/I836) | 10 | 3 |
| Wild-type | 332 | 86 |
| Other molecular aberrations | ||
| Patients tested | 244 | |
| NPM mutations | 14 | 6 |
| CEBPα mutations | 18 | 7 |
| Risk groups | ||
| SR | 99 | 20 |
| HR | 383 | 80 |
| Characteristic . | n . | % . |
|---|---|---|
| Number of evaluable patients | 482 | 100 |
| Gender | ||
| Male | 262 | 52 |
| Female | 220 | 48 |
| Age | ||
| <1 y | 63 | 13 |
| 1-2 y | 52 | 10 |
| 2-10 y | 181 | 38 |
| >10 y | 186 | 39 |
| WBC count (×109/L) | ||
| <10 | 171 | 35 |
| 10-99 | 236 | 49 |
| >100 | 75 | 16 |
| CNS leukemia (yes) | 40 | 8 |
| FAB subtype | ||
| M0 | 34 | 7 |
| M1 | 88 | 18 |
| M2 | 91 | 19 |
| M4 | 40 | 8 |
| M4 Eo | 43 | 9 |
| M5 | 117 | 24 |
| M6 | 5 | 1 |
| M7 | 44 | 9 |
| Unclassifiable/not known | 20 | 4 |
| Cytogenetics | ||
| Patients with available cytogenetic data | 418 | |
| Favorable cytogenetics | 99 | 24 |
| t(8;21) | 72 | 17 |
| t(16;16) | 1 | 0 |
| inv 16 | 26 | 6 |
| Translocation t(9;11) | 19 | 5 |
| Other 11q23 abnormalities | 46 | 11 |
| Complex karyotype | 27 | 6 |
| Normal | 166 | 39 |
| Other abnormalities | 61 | 15 |
| FLT3 aberrations | ||
| Patients tested for FLT3 aberrations | 384 | |
| ITD | 42 | 11 |
| Activating loop mutations (D835/I836) | 10 | 3 |
| Wild-type | 332 | 86 |
| Other molecular aberrations | ||
| Patients tested | 244 | |
| NPM mutations | 14 | 6 |
| CEBPα mutations | 18 | 7 |
| Risk groups | ||
| SR | 99 | 20 |
| HR | 383 | 80 |
CEBPα, CCAAT/enhancer binding protein; ITD, internal tandem duplication; NPM, nucleophosmin.